Signals
AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?
AstraZeneca and Ionis’ eplontersen did not reduce cardiovascular death and recurrent cardiovascular events in the overall CARDIO-TTRansform population. With 57% of participants already receiving a transthyretin stabiliser and another 24% starting one during the study, the result raises a harder question than whether one drug failed: how should regulators and payers judge added benefit when…
Not All Eye Infections Are Equal: New Evidence Points to a Precision Medicine Approach
What happens when surgeons no longer need to be in the same country as their patients?
EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption
As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.
J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Parkinson’s Research Takes Aim at Mitochondrial Failure
Ebola Control Hits the Trust Test
The invisible heart disease crisis: Why congenital heart disease is moving up the global health agenda
A new guideline is changing how health systems think about obesity, diabetes and heart disease
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.